Biofrontera Inc.BFRIEarnings & Financial Report
Biofrontera Inc. is a specialty biopharmaceutical enterprise focused on developing and commercializing prescription dermatological products. Its core product line targets skin conditions including actinic keratosis and other dermatological disorders, with primary operating markets in the United States and European Union, serving patients and dermatology care providers.
Revenue
$7.9M
Gross Profit
N/A
Operating Profit
$-5.5M
Net Profit
$-10.4M
Gross Margin
N/A
Operating Margin
-69.1%
Net Margin
-131.9%
YoY Growth
-9.4%
EPS
$-2.88
Biofrontera Inc. Q1 FY2024 Financial Summary
Biofrontera Inc. reported revenue of $7.9M (down 9.4% YoY) for Q1 FY2024, with a net profit of $-10.4M (down 39.6% YoY) (-131.9% margin).
Key Financial Metrics
| Total Revenue | $7.9M |
|---|---|
| Net Profit | $-10.4M |
| Gross Margin | N/A |
| Operating Margin | -69.1% |
| Report Period | Q1 FY2024 |
Revenue Breakdown
Biofrontera Inc. Q1 FY2024 revenue of $7.9M breaks down across 2 segments, led by Other at $4.0M (50.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $4.0M | 50.1% |
| Related Party | $3.9M | 49.9% |
Biofrontera Inc. Annual Revenue by Year
Biofrontera Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $41.7M).
| Year | Annual Revenue |
|---|---|
| 2025 | $41.7M |
| 2024 | $37.3M |
| 2023 | $34.1M |
| 2022 | $28.7M |
Biofrontera Inc. Quarterly Revenue & Net Profit History
Biofrontera Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $17.1M | +36.2% | $5.6M | 33.0% |
| Q3 FY2025 | $7.0M | -22.5% | $-6.6M | -95.1% |
| Q2 FY2025 | $9.0M | +15.2% | $-5.3M | -59.0% |
| Q1 FY2025 | $8.6M | +8.5% | $-4.2M | -48.9% |
| Q4 FY2024 | $12.6M | +18.5% | $-1.4M | -11.1% |
| Q3 FY2024 | $9.0M | +1.3% | $-5.7M | -62.9% |
| Q2 FY2024 | $7.8M | +34.0% | $-257.0K | -3.3% |
| Q1 FY2024 | $7.9M | -9.4% | $-10.4M | -131.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.9M | $7.8M | $9.0M | $12.6M | $8.6M | $9.0M | $7.0M | $17.1M |
| YoY Growth | -9.4% | 34.0% | 1.3% | 18.5% | 8.5% | 15.2% | -22.5% | 36.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $24.6M | $21.6M | $18.5M | $22.1M | $16.6M | $20.1M | $15.4M | $28.6M |
| Liabilities | $26.4M | $10.7M | $13.0M | $17.7M | $16.1M | $24.8M | $18.0M | $18.1M |
| Equity | $-5.4M | $10.9M | $5.5M | $4.4M | $500000 | $-4.7M | $-2.6M | $10.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.3M | $-4.7M | $-1.2M | $-1.0M | $-4.1M | $-3.0M | $-3.8M | $-2.4M |